{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bekdash R"],"funding":["Irving Medical Center, Columbia University"],"pagination":["e3002522"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10939250"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(3)"],"pubmed_abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the pepti"],"journal":["PLoS biology"],"pubmed_title":["Developing inhibitory peptides against SARS-CoV-2 envelope protein."],"pmcid":["PMC10939250"],"funding_grant_id":["TRx award program","Dean’s Office Fund"],"pubmed_authors":["Ho DD","Nair MS","Huang Y","Yazawa M","Tsai HY","Ahdout J","Bekdash R","Yoshida K","Qiu L","Uryu K","Soni RK"],"additional_accession":[]},"is_claimable":false,"name":"Developing inhibitory peptides against SARS-CoV-2 envelope protein.","description":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the pepti","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-15T07:38:10.609Z","creation":"2026-07-01T03:07:38.639Z"},"accession":"S-EPMC10939250","cross_references":{"pubmed":["38483887"],"doi":["10.1371/journal.pbio.3002522"]}}